Dogwood Therapeutics (DWTX) Competitors

$1.84 +0.03 (+1.38%)

As of 02:01 PM Eastern

DWTX vs. TRDA, ARTV, CNTN, TNXP, and FHTX

Should you buy Dogwood Therapeutics stock or one of its competitors? MarketBeat compares Dogwood Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dogwood Therapeutics include Entrada Therapeutics (TRDA), Artiva Biotherapeutics (ARTV), Hillstream Biopharma (CNTN), Tonix Pharmaceuticals (TNXP), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry.

How does Dogwood Therapeutics compare to Entrada Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Dogwood Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Entrada Therapeutics	$5.74M	43.91	-$143.75M	-$3.99	N/A

Dogwood Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 553.95%. Entrada Therapeutics has a consensus price target of $18.25, indicating a potential upside of 181.20%. Given Dogwood Therapeutics' higher probable upside, research analysts plainly believe Dogwood Therapeutics is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Dogwood Therapeutics had 8 more articles in the media than Entrada Therapeutics. MarketBeat recorded 15 mentions for Dogwood Therapeutics and 7 mentions for Entrada Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.62 beat Entrada Therapeutics' score of 0.38 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Entrada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dogwood Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 0.2% of Dogwood Therapeutics shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dogwood Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Summary

Dogwood Therapeutics and Entrada Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 15 mentions for Dogwood Therapeutics and 14 mentions for Artiva Biotherapeutics. Dogwood Therapeutics' average media sentiment score of 0.62 beat Artiva Biotherapeutics' score of -0.30 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dogwood Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Dogwood Therapeutics has lower revenue, but higher earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	778.78	-$83.86M	-$3.54	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Artiva Biotherapeutics has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

Artiva Biotherapeutics' return on equity of -73.15% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Artiva Biotherapeutics presently has a consensus price target of $39.00, indicating a potential upside of 395.18%. Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 553.95%. Given Dogwood Therapeutics' higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

9.1% of Dogwood Therapeutics shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Artiva Biotherapeutics beats Dogwood Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 6.7% of Hillstream Biopharma shares are held by company insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hillstream Biopharma's return on equity of -31.50% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Hillstream Biopharma has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

In the previous week, Dogwood Therapeutics had 10 more articles in the media than Hillstream Biopharma. MarketBeat recorded 15 mentions for Dogwood Therapeutics and 5 mentions for Hillstream Biopharma. Dogwood Therapeutics' average media sentiment score of 0.62 beat Hillstream Biopharma's score of -0.14 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dogwood Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 553.95%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Dogwood Therapeutics beats Hillstream Biopharma on 9 of the 13 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Tonix Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Tonix Pharmaceuticals has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

In the previous week, Dogwood Therapeutics had 12 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 15 mentions for Dogwood Therapeutics and 3 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.68 beat Dogwood Therapeutics' score of 0.62 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Tonix Pharmaceuticals currently has a consensus price target of $22.00, indicating a potential upside of 69.13%. Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 553.95%. Given Dogwood Therapeutics' higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dogwood Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dogwood Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$17.56M	11.81	-$124.02M	-$14.36	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Summary

Tonix Pharmaceuticals and Dogwood Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Dogwood Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Dogwood Therapeutics has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	8.12	-$74.28M	-$1.16	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 7.6% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Foghorn Therapeutics currently has a consensus price target of $11.43, suggesting a potential upside of 167.40%. Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 553.95%. Given Dogwood Therapeutics' higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Dogwood Therapeutics had 13 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 15 mentions for Dogwood Therapeutics and 2 mentions for Foghorn Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.62 beat Foghorn Therapeutics' score of 0.42 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dogwood Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Foghorn Therapeutics has a beta of 2.97, indicating that its stock price is 197% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

Summary

Foghorn Therapeutics beats Dogwood Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Dogwood Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DWTX vs. The Competition

Export

Metric	Dogwood Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$61.71M	$3.38B	$6.39B	$12.33B
Dividend Yield	N/A	2.30%	2.79%	5.33%
P/E Ratio	-0.17	19.03	21.06	25.70
Price / Sales	N/A	299.85	580.13	99.36
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	0.76	6.98	10.10	7.04
Net Income	-$34.26M	$24.45M	$3.55B	$335.04M
7 Day Performance	0.27%	3.76%	4.91%	2.69%
1 Month Performance	19.93%	-0.17%	1.57%	1.49%
1 Year Performance	-65.38%	62.88%	36.63%	35.72%

Dogwood Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DWTX Dogwood Therapeutics	3.0201 of 5 stars	$1.84 +1.4%	$12.00 +554.0%	-66.0%	$61.71M	N/A	N/A	5	Analyst Forecast Analyst Revision
TRDA Entrada Therapeutics	3.9084 of 5 stars	$5.65 -4.1%	$18.25 +223.0%	-17.9%	$228.65M	$25.42M	N/A	110	Gap Up
ARTV Artiva Biotherapeutics	3.8169 of 5 stars	$8.55 -7.3%	$39.00 +356.1%	+299.5%	$227.89M	$250K	N/A	81	Insider Trade
CNTN Hillstream Biopharma	0.6366 of 5 stars	$3.27 +0.3%	N/A	N/A	$227.56M	N/A	N/A	2
TNXP Tonix Pharmaceuticals	3.7439 of 5 stars	$13.71 -3.9%	$22.00 +60.5%	-50.6%	$227.32M	$13.11M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DWTX) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. TRDA, ARTV, CNTN, TNXP, and FHTX

How does Dogwood Therapeutics compare to Entrada Therapeutics?

Summary

How does Dogwood Therapeutics compare to Artiva Biotherapeutics?

Summary

How does Dogwood Therapeutics compare to Hillstream Biopharma?

Summary

How does Dogwood Therapeutics compare to Tonix Pharmaceuticals?

Summary

How does Dogwood Therapeutics compare to Foghorn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. TRDA, ARTV, CNTN, TNXP, and FHTX

How does Dogwood Therapeutics compare to Entrada Therapeutics?

Which has stronger earnings & valuation, DWTX or TRDA?

Do analysts prefer DWTX or TRDA?

Does the media prefer DWTX or TRDA?

Which has more volatility & risk, DWTX or TRDA?

Do institutionals and insiders have more ownership in DWTX or TRDA?

Is DWTX or TRDA more profitable?

Summary

How does Dogwood Therapeutics compare to Artiva Biotherapeutics?

Does the media favor ARTV or DWTX?

Which has preferable earnings & valuation, ARTV or DWTX?

Which has more risk and volatility, ARTV or DWTX?

Is ARTV or DWTX more profitable?

Do analysts rate ARTV or DWTX?

Do insiders & institutionals have more ownership in ARTV or DWTX?

Summary

How does Dogwood Therapeutics compare to Hillstream Biopharma?

Do institutionals and insiders hold more shares of CNTN or DWTX?

Is CNTN or DWTX more profitable?

Which has better earnings & valuation, CNTN or DWTX?

Which has more volatility & risk, CNTN or DWTX?

Does the media refer more to CNTN or DWTX?

Do analysts prefer CNTN or DWTX?

Summary

How does Dogwood Therapeutics compare to Tonix Pharmaceuticals?

Which has more risk & volatility, TNXP or DWTX?

Does the media refer more to TNXP or DWTX?

Do analysts recommend TNXP or DWTX?

Is TNXP or DWTX more profitable?

Do institutionals & insiders have more ownership in TNXP or DWTX?

Which has better earnings and valuation, TNXP or DWTX?

Summary

How does Dogwood Therapeutics compare to Foghorn Therapeutics?

Is FHTX or DWTX more profitable?

Which has preferable earnings and valuation, FHTX or DWTX?

Do institutionals and insiders believe in FHTX or DWTX?

Do analysts recommend FHTX or DWTX?

Does the media refer more to FHTX or DWTX?

Which has more risk and volatility, FHTX or DWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools